Retatrutide Phase 3: What TRIUMPH-2 and TRIUMPH-3 Actually Reported

Retatrutide's Phase 2 data made it famous. The Phase 3 programme is what determines whether it becomes a medicine — and in 2026 the readouts kept arriving.

Why the triple agonist is different

Retatrutide activates three metabolic receptors at once:

• GLP-1 — satiety, insulin secretion, gastric emptying
• GIP — insulin response, adipose tissue handling
• Glucagon receptor — energy expenditure, hepatic fat metabolism

For comparison: semaglutide targets GLP-1; tirzepatide targets GLP-1 and GIP. The glucagon component is retatrutide's distinguishing feature, and the leading hypothesis for why its weight-loss numbers sit above its predecessors — it appears to raise energy expenditure rather than only reducing intake.

TRIUMPH-2: obesity with type 2 diabetes

1,152 adults with obesity or overweight plus type 2 diabetes, randomised to retatrutide 4mg, 9mg, 12mg or placebo, over 80 weeks.

Mean body-weight reduction from baseline:

• 4mg — 12.7% (≈29.8 lb)
• 9mg — 19.1% (≈45.4 lb)
• 12mg — 20.8% (≈49.6 lb)
• Placebo — 4.0% (≈9.3 lb)

That context matters: people with type 2 diabetes have historically lost weight more slowly than those without it on the same agents. Exceeding 20% in this population is the notable part, not the headline percentage in isolation.

Glycaemic control, from a baseline A1C of 7.7%:

• 4mg — −1.4%
• 9mg — −1.6%
• 12mg — −1.5%
• Placebo — −0.2%

TRIUMPH-3: severe obesity with cardiovascular disease

1,949 participants with BMI ≥35 and established cardiovascular disease, with or without type 2 diabetes, receiving 9mg, 12mg or placebo.

This is the harder population and, arguably, the more clinically meaningful one — cardiovascular outcomes are what regulators and payers weigh most heavily.

Across the programme

Combining the readouts reported to date:

• Up to 22.6% average body-weight reduction
• Up to 25.3 kg (55.8 lb) average weight loss
• Up to 1.6% A1C reduction
• Improvements reported across triglycerides, blood pressure, inflammatory markers and waist circumference
• Positive results across five completed Phase 3 studies
• Eli Lilly has stated it plans to submit a Biologics License Application to the FDA in Q1 2027

What the numbers don't say

• Gastrointestinal adverse events remain the dominant tolerability issue across the class
• Dose-dependent heart rate increases were observed in earlier trials and warrant continued attention
• Trial populations are selected; they are not a general population
• Weight regain after discontinuation has been the pattern across the incretin class and there is no reason yet to assume retatrutide is exempt
• Percentages are group means. Individual response distributions are wide.

The classification question

Retatrutide is being filed as a biologic, not a small molecule. That's a regulatory distinction with real downstream consequences for how it can be produced, compounded and accessed once approved — and it's the reason discussion of retatrutide availability has changed tone through 2026.

For researchers

The Phase 3 data narrow the uncertainty considerably on efficacy and shift the interesting questions elsewhere: durability after cessation, lean-mass preservation, the specific contribution of glucagon agonism to energy expenditure, and how triple agonism behaves in populations the trials excluded.

EVERKIND stocks Retatrutide in 10mg, 20mg and 30mg presentations for laboratory research use.

Disclaimer: This article is educational only. All compounds discussed are supplied strictly for laboratory research use and are not approved for human or veterinary use.